Literature DB >> 29318006

Naloxone dosage for opioid reversal: current evidence and clinical implications.

Rachael Rzasa Lynn1, J L Galinkin2.   

Abstract

Opioid-related mortality is a growing problem in the United States, and in 2015 there were over 33,000 opioid-related deaths. To combat this mortality trend, naloxone is increasingly being utilized in a pre-hospital setting by emergency personnel and prescribed to laypersons for out-of-hospital administration. With increased utilization of naloxone there has been a subsequent reduction in mortality following an opioid overdose. Reversal of opioid toxicity may precipitate an opioid-withdrawal syndrome. At the same time, there is a risk of inadequate response or re-narcotization after the administration of a single dose of naloxone in patients who have taken large doses or long-acting opioid formulations, as the duration of effect of naloxone is shorter than that of many opioid agonists. As out-of-hospital use of this medication is growing, so too is concern about effective but safe dosing.

Entities:  

Keywords:  harm reduction; naloxone; opioid overdose; route of administrations

Year:  2017        PMID: 29318006      PMCID: PMC5753997          DOI: 10.1177/2042098617744161

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN: 2042-0986


  173 in total

1.  Naloxone treatment of opiate dependence. A progress report.

Authors:  A Zaks; T Jones; M Fink; A M Freedman
Journal:  JAMA       Date:  1971-03-29       Impact factor: 56.272

2.  Effect of naloxone reversal on CO2 output, oxygen uptake and cardiac index during recovery from fentanyl-supplemented anaesthesia.

Authors:  I Tigerstedt; T Tammisto
Journal:  Acta Anaesthesiol Scand       Date:  1978       Impact factor: 2.105

3.  Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania.

Authors:  Alex S Bennett; Alice Bell; Laura Tomedi; Eric G Hulsey; Alex H Kral
Journal:  J Urban Health       Date:  2011-12       Impact factor: 3.671

4.  Overdose prevention and naloxone prescription for opioid users in San Francisco.

Authors:  Lauren Enteen; Joanna Bauer; Rachel McLean; Eliza Wheeler; Emalie Huriaux; Alex H Kral; Joshua D Bamberger
Journal:  J Urban Health       Date:  2010-12       Impact factor: 3.671

5.  Notes from the Field: Furanyl-Fentanyl Overdose Events Caused by Smoking Contaminated Crack Cocaine - British Columbia, Canada, July 15-18, 2016.

Authors:  Salman A Klar; Elizabeth Brodkin; Erin Gibson; Shovita Padhi; Christine Predy; Corey Green; Victoria Lee
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-09-23       Impact factor: 17.586

6.  Opioid overdose prevention with intranasal naloxone among people who take methadone.

Authors:  Alexander Y Walley; Maya Doe-Simkins; Emily Quinn; Courtney Pierce; Ziming Xuan; Al Ozonoff
Journal:  J Subst Abuse Treat       Date:  2012-09-12

7.  Treatment of heroin overdose with endotracheal naloxone.

Authors:  D Tandberg; D Abercrombie
Journal:  Ann Emerg Med       Date:  1982-08       Impact factor: 5.721

8.  Evaluation of the Staying Alive programme: training injection drug users to properly administer naloxone and save lives.

Authors:  Karin E Tobin; Susan G Sherman; Peter Beilenson; Christopher Welsh; Carl A Latkin
Journal:  Int J Drug Policy       Date:  2008-04-22

Review 9.  A systematic review of community opioid overdose prevention and naloxone distribution programs.

Authors:  Angela K Clark; Christine M Wilder; Erin L Winstanley
Journal:  J Addict Med       Date:  2014 May-Jun       Impact factor: 3.702

10.  A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia.

Authors:  H P Adams; C P Olinger; W G Barsan; M J Butler; N R Graff-Radford; T G Brott; J Biller; H Damasio; T Tomsick; M Goldberg
Journal:  Stroke       Date:  1986 May-Jun       Impact factor: 7.914

View more
  58 in total

1.  A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats.

Authors:  Michael D Raleigh; Federico Baruffaldi; Samantha J Peterson; Morgan Le Naour; Theresa M Harmon; Jennifer R Vigliaturo; Paul R Pentel; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2018-11-08       Impact factor: 4.030

Review 2.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

Review 3.  Pharmacotherapeutic management of co-morbid alcohol and opioid use.

Authors:  Lauren E Hood; Jonna M Leyrer-Jackson; M Foster Olive
Journal:  Expert Opin Pharmacother       Date:  2020-02-27       Impact factor: 3.889

4.  Naloxone perspectives from people who use opioids: Findings from an ethnographic study in three states.

Authors:  Miriam Boeri; Aukje K Lamonica
Journal:  J Am Assoc Nurse Pract       Date:  2020-04-01       Impact factor: 1.165

Review 5.  Opioid antagonists as potential therapeutics for ischemic stroke.

Authors:  Nadia Peyravian; Emre Dikici; Sapna Deo; Michal Toborek; Sylvia Daunert
Journal:  Prog Neurobiol       Date:  2019-08-06       Impact factor: 11.685

Review 6.  Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Authors:  Sandra D Comer; Catherine M Cahill
Journal:  Neurosci Biobehav Rev       Date:  2018-12-05       Impact factor: 8.989

7.  Calabadion 1 selectively reverses respiratory and central nervous system effects of fentanyl in a rat model.

Authors:  Tharusan Thevathasan; Stephanie D Grabitz; Peter Santer; Paul Rostin; Oluwaseun Akeju; James D Boghosian; Monica Gill; Lyle Isaacs; Joseph F Cotten; Matthias Eikermann
Journal:  Br J Anaesth       Date:  2020-03-30       Impact factor: 9.166

8.  Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats.

Authors:  Carly Baehr; April Huseby Kelcher; Aaron Khaimraj; Dana E Reed; Sujata G Pandit; David AuCoin; Saadyah Averick; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2020-09-26       Impact factor: 4.030

Review 9.  Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis.

Authors:  Randy Torralva; Aaron Janowsky
Journal:  J Pharmacol Exp Ther       Date:  2019-09-06       Impact factor: 4.030

10.  Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone.

Authors:  Andrew J Kassick; Heather N Allen; Saigopalakrishna S Yerneni; Fathima Pary; Marina Kovaliov; Cooper Cheng; Marco Pravetoni; Nestor D Tomycz; Donald M Whiting; Toby L Nelson; Michael Feasel; Phil G Campbell; Benedict Kolber; Saadyah Averick
Journal:  ACS Appl Bio Mater       Date:  2019-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.